BrECADD therapy for stage 2B to stage 4 Hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination drug treatment called BrECADD for people with Hodgkin lymphoma that has certain risk factors or is in a more advanced stage (stage 2B, 3, or 4). It aims to see if this treatment works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with classical Hodgkin lymphoma (a specific type of lymphoma).
- Your lymphoma is at stage 2B with a large chest mass or disease outside the lymph nodes, or at stage 3 or 4.
- You have not had any previous treatment for lymphoma with strong chemotherapy or brentuximab vedotin.
- Your overall health is good enough for daily activities (ECOG score 0 to 2).
- You agree to use effective birth control during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
This trial tests a combination of the targeted drug brentuximab vedotin with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) for adults with Stage 3 or 4 Hodgkin lymphoma who have not had previous treatment. It aims to see if this combination works well and is safe.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.